Millennium Pharmaceuticals, Inc.; Millennium announces phase II data for MLN02
Millennium Pharmaceuticals, Inc.; Millennium announces phase II data for MLN02
About this item
Full title
Millennium Pharmaceuticals, Inc.; Millennium announces phase II data for MLN02
Publisher
Atlanta: NewsRx
Journal title
Biotech Week, 2002, p.60
Language
English
Formats
Publication information
Publisher
Atlanta: NewsRx
More information
Scope and Contents
Contents
MLN02 is an investigational monoclonal antibody that binds to a T- cell integrin, alpha4beta7, and has been shown to prevent the migration of T cells to the gut in laboratory studies. Increased T- cell trafficking is believed to play a role in the pathogenesis of [Crohn] disease and ulcerative colitis (inflammatory bowel diseases). MLN02 is also be...
Alternative Titles
Full title
Millennium Pharmaceuticals, Inc.; Millennium announces phase II data for MLN02
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_205514940
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_205514940
Other Identifiers
ISSN
1535-2757
E-ISSN
1537-1395
How to access this item
Log in as a Library member
